ResMed offers therapy solutions for those suffering from chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), amyotrophic lateral sclerosis (ALS) and respiratory failure.
Our ventilation solutions improve the quality of life for patients with respiratory diseases. We offer market leading mechanical ventilation for respiratory failure stemming from congenital defects, illness, trauma, obesity, cardiac arrest, neuromuscular disease, pulmonary disease and sepsis and shock. We also provide noninvasive ventilation (NIV) solutions for patients who need short- or long- term ventilation, in both hospital and home settings.
An estimated 80 million people worldwide have moderate-to-severe COPD, and COPD deaths are predicted to increase by more than 30 percent in the next decade. Studies show that one in five patients with stage 3 or 4 COPD hospitalized for acute respiratory exacerbations are readmitted to the hospital within 30 days. Treatment at home with NIV can decrease the chances of hospitalization, and can be an effective cost saving measure for patients and healthcare providers.
In 2013 ResMed released the VPAP™ COPD, a bilevel therapy device cleared by the U.S. Food and Drug Administration (FDA) for the treatment of COPD. This device gives patients with COPD a weapon in the fight to stay out of the hospital, and helps lead to a better quality of life by slowing the progression of COPD. Our ClimateLineMAX™ Oxy tubing has an oxygen line port near the mask so that patients who need supplemental oxygen can decrease the amount of tubing near their mask.
 World Health Organization, 2013. http://www.who.int/mediacentre/factsheets/fs315/en/. Last accessed September 19, 2013.
 Cheung et al. A pilot trial of non-invasive ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2010; 14(5):642-649
 Tuggey JM, Plant PK, Elliot MW. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. Thorax: 2003:, Oct; 58(10):867-71